Vanguard Group’s Acceleron Pharma XLRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-4,925,189
| Closed | -$848M | – | 4702 |
|
|
2021
Q3 | $848M | Buy |
4,925,189
+14,836
| +0.3% | +$1.94M | 0.02% | 709 |
|
|
2021
Q2 | $616M | Sell |
4,910,353
-166,342
| -3% | -$21M | 0.02% | 861 |
|
|
2021
Q1 | $688M | Buy |
5,076,695
+48,117
| +1% | +$6.22M | 0.02% | 775 |
|
|
2020
Q4 | $643M | Buy |
5,028,578
+330,377
| +7% | +$38.7M | 0.02% | 755 |
|
|
2020
Q3 | $529M | Buy |
4,698,201
+363,888
| +8% | +$36.2M | 0.02% | 756 |
|
|
2020
Q2 | $413M | Buy |
4,334,313
+73,145
| +2% | +$7.05M | 0.01% | 843 |
|
|
2020
Q1 | $383M | Buy |
4,261,168
+96,021
| +2% | +$7.46M | 0.02% | 785 |
|
|
2019
Q4 | $221M | Sell |
4,165,147
-10,374
| -0.2% | -$473K | 0.01% | 1330 |
|
|
2019
Q3 | $165M | Buy |
4,175,521
+88,808
| +2% | +$3.85M | 0.01% | 1450 |
|
|
2019
Q2 | $168M | Buy |
4,086,713
+75,465
| +2% | +$3.12M | 0.01% | 1466 |
|
|
2019
Q1 | $187M | Buy |
4,011,248
+488,620
| +14% | +$21.5M | 0.01% | 1388 |
|
|
2018
Q4 | $153M | Buy |
3,522,628
+97,265
| +3% | +$4.86M | 0.01% | 1422 |
|
|
2018
Q3 | $196M | Buy |
3,425,363
+849,608
| +33% | +$41.8M | 0.01% | 1399 |
|
|
2018
Q2 | $125M | Buy |
2,575,755
+76,657
| +3% | +$2.79M | 0.01% | 1665 |
|
|
2018
Q1 | $97.7M | Buy |
2,499,098
+60,720
| +2% | +$2.58M | ﹤0.01% | 1725 |
|
|
2017
Q4 | $103M | Buy |
2,438,378
+108,330
| +5% | +$4.06M | ﹤0.01% | 1698 |
|
|
2017
Q3 | $87M | Buy |
2,330,048
+301,008
| +15% | +$10.4M | ﹤0.01% | 1784 |
|
|
2017
Q2 | $61.7M | Buy |
2,029,040
+116,705
| +6% | +$3.38M | ﹤0.01% | 1912 |
|
|
2017
Q1 | $50.6M | Buy |
1,912,335
+158,714
| +9% | +$4.18M | ﹤0.01% | 2005 |
|
|
2016
Q4 | $44.8M | Buy |
1,753,621
+69,368
| +4% | +$2.2M | ﹤0.01% | 2030 |
|
|
2016
Q3 | $61M | Buy |
1,684,253
+38,019
| +2% | +$1.26M | ﹤0.01% | 1844 |
|
|
2016
Q2 | $55.9M | Buy |
1,646,234
+181,375
| +12% | +$5.9M | ﹤0.01% | 1851 |
|
|
2016
Q1 | $38.7M | Buy |
1,464,859
+200,473
| +16% | +$5.83M | ﹤0.01% | 1983 |
|
|
2015
Q4 | $61.7M | Buy |
1,264,386
+26,721
| +2% | +$961K | ﹤0.01% | 1786 |
|
|
2015
Q3 | $30.8M | Buy |
1,237,665
+374,168
| +43% | +$11.2M | ﹤0.01% | 2093 |
|
|
2015
Q2 | $27.3M | Buy |
863,497
+73,121
| +9% | +$2.36M | ﹤0.01% | 2216 |
|
|
2015
Q1 | $30.1M | Buy |
790,376
+15,507
| +2% | +$617K | ﹤0.01% | 2158 |
|
|
2014
Q4 | $30.2M | Buy |
774,869
+39,542
| +5% | +$1.38M | ﹤0.01% | 2073 |
|
|
2014
Q3 | $22.2M | Buy |
735,327
+48,799
| +7% | +$1.37M | ﹤0.01% | 2164 |
|
|
2014
Q2 | $23.3M | Buy |
686,528
+299,820
| +78% | +$10M | ﹤0.01% | 2160 |
|
|
2014
Q1 | $13.3M | Buy |
386,708
+253,532
| +190% | +$11.4M | ﹤0.01% | 2359 |
|
|
2013
Q4 | $5.27M | Buy |
+133,176
| New | +$3.21M | ﹤0.01% | 2777 |
|
Vanguard Group's XLRN Position: Q4 2021 in Review
Vanguard Group sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 4,925,189 shares — an estimated $848M sold.
Vanguard Group first reported a position in XLRN in Q4 2013 and held it in 32 quarters. The position peaked at $848M in Q3 2021. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.
- Vanguard Group reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
- Vanguard Group sold 4,925,189 Acceleron Pharma shares in Q4 2021, an estimated $848M.
- Vanguard Group first reported a position in Acceleron Pharma in Q4 2013 and held it in 32 quarters.
- Vanguard Group's Acceleron Pharma position peaked at $848M in Q3 2021.
- 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.
Based on Vanguard Group's 13F filing for Q4 2021, filed 14 Feb 2022.